Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Stock Report

Mkt Cap: US$198.7m

Y-mAbs Therapeutics Future Growth

How is Y-mAbs Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


32.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:YMAB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202593-39N/AN/A4
12/31/202486-53-99-996
12/31/202364-70-103-999
9/30/202243-134-102-101N/A
6/30/202240-135-100-100N/A
3/31/202240-117-96-96N/A
12/31/202135-55-104-103N/A
9/30/202146-38-87-86N/A
6/30/202137-42-93-92N/A
3/31/202126-60-102-101N/A
12/31/202021-119-91-91N/A
9/30/2020N/A-123-99-98N/A
6/30/2020N/A-114-97-95N/A
3/31/2020N/A-91-84-82N/A
12/31/2019N/A-81-75-73N/A
9/30/2019N/A-72-63-62N/A
6/30/2019N/A-59-51-50N/A
3/31/2019N/A-52-48-48N/A
12/31/2018N/A-43-41-41N/A
9/30/2018N/A-38-34-34N/A
6/30/2018N/A-31-28-27N/A
3/31/2018N/A-24-19-19N/A
12/31/2017N/A-19-16-16N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: YMAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: YMAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: YMAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: YMAB's revenue (21.7% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: YMAB's revenue (21.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: YMAB is forecast to be unprofitable in 3 years.


Discover growth companies